Picture of Sinovac Biotech logo

SVA Sinovac Biotech Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareMicro Cap

Annual cashflow statement for Sinovac Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:20-F20-F20-F20-F20-F
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line36.165.218514,45988.1
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items7.532.9518.581.1149
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital-44-28.2283461-1,081
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Cash from Operating Activities7.9439.147915,353-771
Capital Expenditures-5.61-10.6-128-720-403
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-19.6-31.8-77.1-2,304-5,357
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-25.3-42.5-205-3,024-5,760
Financing Cash Flow Items3.81.485584.3226.1
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities64.21.74593-1,897-241
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash42.2-2.2989410,570-7,333